Plain-English translation of NCT07157774 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large Phase 3 trial testing a medication called in adults with elevated lipoprotein(a)—a type of cholesterol particle linked to heart disease. is given by mouth once daily, and researchers want to see whether it can reduce the risk of heart attacks, strokes, and other serious heart events in people who have already experienced cardiovascular problems or are at high risk for them.
High lipoprotein(a) is a significant but often overlooked risk factor for heart disease that doesn't respond well to standard cholesterol medications. This trial exists to test whether the medication can offer a new treatment option for people with this condition who remain at risk despite current therapies.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication or a placebo (a pill that looks identical but contains no active drug) taken by mouth daily. You'll attend clinic visits for blood tests, heart monitoring, and assessments to track your cardiovascular health. The trial is designed to follow participants over time to measure whether the medication reduces the risk of heart attacks, strokes, and related events.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States